علاج سرطان الدم النقوي الحاد التحسسي المتعاود أو المقاوم للعلاج

References

1. Patients relapsing after ATRA and ChT or relapsing >24 months after the end of ATO/ATRA treatment should receive ATO/ATRA for reinduction and consolidation until achievement of second molecular remission [IV, B].
2. In the unlikely event of an early relapse (within 24 months) after treatment with ATO/ATRA, we recommend ATRA with ChT or, in patients not eligible for ChT, GO with or without ATO/ATRA [IV, B] (Figure 5).
3. Treatment of patients with CNS involvement should include ATO, which crosses the blood-brain barrier to some extent (CSF ATO levels were 17.7% of plasma levels).